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The lack of effective drugs in stage IV melanoma has impacted the effectiveness of adjuvant therapies in stage II/III
disease. To date, chemotherapy, immunostimulants and vaccines have been used with minimal success. Interferon
(IFN) has shown an effect on relapse-free survival (RFS) in several clinical trials; however, without a clinically signiﬁcant
effect on overall survival (OS). A recently conducted meta-analysis demonstrated prolongation of disease-free survival
(DFS) in 7% and OS beneﬁt in 3% of IFN-treated patients when compared with observation-only patients. There were
no clear differences for the dose and duration of treatment observed. Observation is still an appropriate control arm in
adjuvant clinical trials. Regional differences exist in Europe in the adjuvant use of IFN. In Northwest Europe, IFN is
infrequently prescribed. In Central and Mediterranean Europe, dermatologists commonly prescribe low-dose IFN
therapy for AJCC stage II and III disease. High-dose IFN regimens are not commonly used. The population of patients
that may beneﬁt from IFN needs to be further characterised, potentially by ﬁnding biomarkers that can predict
response. Such studies are ongoing.
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systemic adjuvant therapies
(chemotherapy, non-speciﬁc immune
stimulants and vaccines)
No less than 25 randomised trials have been conducted in stage
II/III melanoma in order to evaluate adjuvant therapies, such as
chemotherapy, non-speciﬁc immune stimulants such as
bacillus Calmette-Guerin (BCG), Corynebacterium parvum,
levamisole or combinations of these agents with dacarbazine
chemotherapy. These trials were almost invariably
underpowered and yielded negative results with the exception
of occasional, incidental and non-repeatable positive ﬁndings
in trials involving small numbers of patients [1].
Of seven large, randomised trials of allogeneic melanoma
cell-based vaccines conducted, only one trial came close to
demonstrating a treatment beneﬁt. This was an Australian
study investigating an allogeneic tumour cell-based oncolysate
[2]. In the United States, a trial of the Melacine vaccine in stage
II patients showed no beneﬁt for the total study population [3],
but there appeared to be some activity in patients with
particular HLA types [4]. Unfortunately, a prospective study of
the vaccine in patients with these HLA types has not been
conducted. In 2006, there were negative results reported from
two large, randomised trials of Canvaxin, an allogeneic tumour
cell-based vaccine, in patients with stage III and resected stage
IV disease. Patients in the vaccine arms of these trials had worse
outcomes than those in the control arms [5]. Canvaxin had
shown great promise in early case–control studies. The result of
these two trials is a powerful reminder of the unreliability of
such methodology. It demonstrates the limited value of such
data, which should be restricted to generating hypotheses [6].
There was a small, phase III trial of the ganglioside GM2 that
demonstrated a survival beneﬁt for stage III patients. However,
this beneﬁt was observed in only a subset of patients who were
sero-negative for ganglioside antibodies before trial entry [7].
This study led to the European Organisation for Research and
Treatment of Cancer (EORTC) conducting a phase III adjuvant
trial of GM2 in patients with stage II disease (18961) where
1314 patients were accrued and 50% of these patients were
staged by sentinel node biopsy. At the second interim analysis
(2007), it appeared that there might be a detrimental outcome
for survival in the vaccine arm, which led to an early
termination of this trial [8]. The ﬁnal outcome is not yet
known.
interferon alpha
clinical trial data
The use of high-dose IFN (HDI, 20 MIU/m
2 i.v. 5 days per
week for 4 weeks, 10 MIU/m
2 s.c. 3 days a week for 48 weeks)
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EMEA in Europe for patients with high-risk melanoma (stage
IIB/III). HDI is commonly used in the United States, although
it is not commonly used in Europe. The therapeutic impact on
OS is uncertain and considered modest at best, the side-effect
proﬁle is signiﬁcant and the cost can be relatively high [1, 9].
Gogas et al. [10] recently reported that 4 weeks of
intravenous IFN (15 MIU i.v. 5 days per week for 4 weeks) was
as good as the 4-week regimen followed by 10 MIU ﬂat dose s.c.
3 days a week for 48 weeks), and was much better tolerated. The
dosing schedule used in that trial differs from the HDI regimen
approved by the FDA and EMEA.
The ECOG is currently conducting an adjuvant trial in
patients with stage II (T3N0, tumour thickness 1.5–4.0 mm) or
stage III (T4N0, tumour thickness >4 mm) melanoma without
nodal involvement and in patients with stage III (T1–4, N1)
melanoma with a microscopically positive lymph node (ECOG
1697), comparing 4 weeks of high-dose IFN-a2b with
observation alone. Due to the present rates of accrual, it is likely
that these results will not be available before 2010.
Intermediate doses of IFN (IDI) were tested in patients with
stage IIB/III disease in the largest phase III trial to date (EORTC
18952). The results demonstrated a statistically insigniﬁcant
7.2% increase in distant metastasis-free interval (hazard ratio
0.83; 97.5% CI 0.66–1.03; P = 0.05) and a 5.4% increase in OS
(hazard ratio 0.85; 97.5% CI 0.68–1.07; P = 0.12) at 4.65 years
of follow-up.
The increase in OS was observed only in patients treated for
25 months with 5 MIU IFN-a2b and not in those treated for 13
months with 10 MIU IFN-a2b [11].These results suggested that
duration of therapy might be more important than dose.
The question of treatment duration was addressed in the next
EORTC trial (18991) in which patients were randomised to 5
years of pegylated IFN-a2b (PEG-IFN) or to observation alone
[12]. In this trial, the dosing schedule was comparable to that of
HDI. PEG-IFN was administered for an induction period of 8
weeks at 6 lg/kg body weight, followed by long-term
maintenance dosing of 3 lg/kg for the remaining 5 years. This
was a registration study, and the trial endpoint set by the
regulatory authority was relapse-free survival (RFS), although
the primary endpoint of the trial was distant metastasis-free
survival (DMFS) with OS and toxicity as secondary endpoints.
The trial results to date are consistent with that of other phase
III trials of adjuvant IFN having a signiﬁcant effect on RFS and
no signiﬁcant impact on DMFS or OS at 4 years (Table 1). In
patients with only microscopic involvement of regional lymph
nodes (sentinel node biopsy-positive patients, N1) the impact on
DMFS was statistically signiﬁcant (Table 2), with a trend to
prolongation of OS, compared with those patients with palpable
disease. In those with palpable nodal involvement (N2), there
was no signiﬁcant impact of PEG-IFN therapy on either
endpoint. The beneﬁts in OS and DMFS for patients with
microscopic nodal involvement were very similar to those
observed in the 25-month IFN treatment arm in the EORTC
18952 trial.
Thus, a signiﬁcant or borderline signiﬁcant impact on
early stage III disease has been observed in two consecutive
EORTC trials involving 2644 patients, whereas there was no
impact on outcome in patients with palpable nodal
involvement in either study. This observation underscores
the value of sentinel node (SN) biopsy as the current
widespread practice that enables accurate patient staging at
trial entry. A Dermatological Cooperative Oncology Group
(DeCOG) study compared administration of low-dose IFN-
a2a (3 · 3 MIU/week) for 18 months, as approved in
Europe, with administration for 60 months. The trial
included 850 patients with primary melanoma of >1.5 mm
tumour thickness, with the majority of the patients staged
by sentinel node biopsy. No difference in disease-free
survival (DFS) or OS has been observed between the groups
so far [13].
Low-dose IFN trials. The effect of low-dose IFN (LDI) in
stage II and III melanoma was also tested [14]. In stage II, LDI
had a consistent and signiﬁcant effect on DFS in the French
[15], Austrian [16] and Scottish [17] studies, with even
a borderline signiﬁcant effect on OS in the French trial [15]
(Table 3). LDI regimens of 2 and 3 years in stage IIB and III
disease were tested in the Intergroup 1690 [18] and in the
UKCCR Aim High [19] trials with a similar small effect on
DFS. The WHO-16 trial, which evaluated 3 years of LDI in
stage IIIB or IIIC patients, was negative for both DFS and OS
[20]. Thus, earlier disease appears more responsive to LDI than
more advanced disease.
In contrast, very recent results of a LDI DeCOG trial showed
improvement in both DFS and OS for low-dose IFN-treated
patients compared with untreated controls in stage III
melanoma, while the combination of LDI and dacarbazine did
not demonstrate any beneﬁt [21]. Low-dose IFN therapy has
been approved as an adjuvant therapy for stage II patients by
the EMEA in Europe. The effect of IFN in stage II/III patient
trials, at the time when these patients were not SN-staged,
corresponds well with the observations in the EORTC 18952
and 18991 trials, where the greatest effect was observed in
patients with positive sentinel nodes.
At least four prospective, cooperative group, randomised
multicentre trials have demonstrated that a combination of
low-dose IFN-a with other agents does not improve outcome
(Table 4). Patients with stage IIIA, B or C melanoma were
treated in a DeCOG trial with dacarbazine plus LDI or LDI
alone for 2 years, and compared with observation alone.
Surprisingly, the combination of dacarbazine plus LDI
diminished the treatment effects observed with LDI alone. The
possible detrimental effect of dacarbazine in the adjuvant
setting requires further consideration [21].
Table 1. Signiﬁcant impact of pegylated IFN-a2b (PEG-IFN) on disease-
free survival (DFS) but not on distant metastasis-free survival (DMFS)
and overall survival (OS) in patients with stage III melanoma (data taken
from ref. [12])
DFS DMFS OS
PEG-IFN
a 45.6% (2.2) 48.2% (2.2) 56.8% (2.2)
Observation
a 38.9% (2.2) 45.4% (2.3) 55.7% (2.1)
HR (95% CI)
b 0.82 (0.71–0.96) 0.88 (0.75–1.03) 0.98 (0.82–1.16)
P-value
b 0.01 0.11 0.78
a4-year rate (SE).
bUnivariate analysis.
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combined an allogeneic melanoma lysate vaccine (Melacine)
with low-dose IFN-a. This regimen was compared with high-
dose IFN-a2b alone. No differences in DFS or OS were
observed [22]. A DeCOG trial of LDI combined with low-dose
interleukin-2 (IL-2) presented overlapping survival curves for
DFS and OS compared with untreated controls [23]. A
randomised, double-blinded, placebo-controlled trial from
Austria comparing LDI and isotretinoin with IFN-a alone in
stage IIA/IIB melanoma patients was stopped for futility [24].
In conclusion, the combination of low-dose IFN-a with
various other agents, which might have an additional or
synergistic effect, is no better than LDI or observation alone.
A systematic review of all trials [25], a meta-analysis of all
trials [26] and a pooled data analysis of all HDI trials [27]
demonstrated a consistent DFS improvement but no
statistically signiﬁcant impact on OS. The clinical relevance of
improvements in DFS is unclear and is difﬁcult to quantify. An
individual patient data-based meta-analysis was reported at the
43rd Annual Meeting of ASCO in 2007 [14], which conﬁrmed
the consistently reported, statistically signiﬁcant beneﬁt on DFS
(7%), and for the ﬁrst time, a small but statistically signiﬁcant
impact (3%) on OS. This effect is partly due to the inclusion of
trials ECOG 1694 and ECOG 2696, which had the ganglioside
GM2 vaccine as a comparator arm. The validity of inclusion of
these trials has been questioned. The EORTC 18961 trial was
terminated based on the second interim analysis of a potential
detrimental effect of the vaccine. Another important ﬁnding
from this individual patient data-based meta-analysis is that the
effects of IFN were observed across a wide range of doses. The
conclusions drawn were that the therapeutic effect of IFN is not
dose related, nor related to treatment duration.
predictive factors: auto-antibodies
Gogas et al. [28] have reported that patients treated with
adjuvant IFN who developed auto-antibodies against
thyroglobulin, antinuclear antibodies or cardiolipin have
a signiﬁcantly better outcome than patients without these signs
of autoimmunity. The observation that autoimmunity is
Table 2. Signiﬁcant impact of pegylated IFN-a2b (PEG-IFN) on disease-free survival (DFS) and distant metastasis-free survival (DMFS) in stage III
melanoma patients with N1 microscopic but not N2 macroscopic nodal involvement (data taken from ref. [12])
DFS DMFS
N1 N2 N1 N2
aPEG-IFN 57.7% (3.3) 36.3% (2.8) 60.5% (3.6) 38.7% (2.8)
aObservation 45.4% (3.5) 33.9% (2.6) 52.6% (3.5) 39.9% (2.7)
bHR (99%CI) 0.73 (0.53–1.02) 0.86 (0.68–1.10) 0.75 (0.52–1.07) 0.94 (0.73–1.21)
bP-value 0.016 0.12 0.03 0.53
a4-year rate (SE).
bUnivariate analysis.
Table 3. Low-dose IFN trials in stage II/III melanoma
Trial Stage Treatment DFS OS
French [15] II IFN-a2a, 3 · 3 MIU/week for 18 months 5-year; HR = 0.75; P = 0.035 5-year; HR = 0.72; P = 0.059
Austrian [16] II IFN-a2a, 3 · 3 MIU/day for 3 weeks;
3 · 3MIU/week for 12 months
3.4-year; HR = 0.62; P = 0.02 3.4-year; HR = 0.83;
not signiﬁcant
Scottish [17] IIB, III IFN-a2b, 3 · 3 MIU/week for 6 months 2-year; HR = 0.72; P = 0.05 2-year; HR = 0.81; P > 0.2
ECOG 1690 [18] IIB, III IFN-a2b, 3 · 3 MIU/week for 24 months 5-year; HR = 0.90; P = 0.17 5-year; HR = 0.93; P = 0.81
UKCCR [19] IIB, III IFN-a2a, 3 · 3 MIU/week for 24 months 5-year; HR = 0.91; P = 0.3 5-year; HR = 0.94; P = 0.6
WHO-16 [20] III IFN-a2a, 3 · 3 MIU/week for 36 months 5-year; HR = 0.95; P = 0.5 5-year; HR = 0.96; P > 0.5
DeCOG [21] III IFN-a2a, 3 · 3 MIU/week, for 24 months 4-year; HR = 0.69; P = 0.018 4-year; HR = 0.62; P = 0.0045
DFS, disease-free survival; HR, hazard ratio; OS, overall survival.
Table 4. Combination trials with low-dose IFN
Trial Combination Stage DFS OS
Garbe et al. [21] IFN-a2a + dacarbazine
a,c III 4-year; P = 0.97 4-year; P = 0.75
Mitchell et al. [22] IFN-a2b + Melacine
b III 5-year, P = 0.80 5-year; P = 0.57
Hauschild et al. [23] IFN-a2b + IL-2
c II 6.6-year; P = 0.93 6.6-year; P = 0.93
Richtig et al. [24] IFN-a2a + isotretinoin
a II 5-year; P = 0.25 5-year; P = 0.80
Control arms:
alow-dose IFN;
bhigh-dose IFN;
cobservation.
DFS, disease-free survival; OS, overall survival.
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longer DFS and OS has been known for many years. This
association not only applies to patients treated with
immunotherapy, but also to patients administered chemotherapy
andsometimesnotherapyatall.Theidentiﬁcationofmarkersthat
might predict a host antitumour immune response is extremely
important. These could be used to determine which patients to
treat with IFN and for what duration of time.
An evaluation of the presence or emergence of auto-
antibodies in patients who participated in EORTC 18952 did
not conﬁrm Gogas’s observations [29]. Also, a sub-study of the
ECOG 2696 trial did not conﬁrm auto-antibodies as a strong
independent prognostic factor [30], nor did antibodies have
any prognostic value in EORTC 18991 [31].
In contrast, serial determination of serum S100 levels was
demonstrated to be a very powerful prognostic factor in an
analysis of the EORTC 18952 trial on intermediate doses of IFN
in stage IIB/III patients, and its prognostic value was even
superior to the number of positive regional lymph nodes [32].
other ongoing and future trials
Novel targeted agents, anti-angiogenics and immune
modulators are being actively investigated in stage IV
melanoma, while agents such as bevacizumab and anti-CTLA-4
are already in adjuvant studies. An analysis of the adjuvant
phase III trial of anti-CTLA-4 antibody ipilimumab (EORTC
18071) starting in 2008, will not be complete before 2011.
A study of pegylated IFN in high-risk, stage II patients with
ulcerated melanomas (EORTC 18081) will begin shortly.
conclusions
After decades of research, cytotoxic drugs, immune stimulants and
vaccines have had disappointing results in the adjuvant setting.
IFN-a is the major drug that has been considered for adjuvant
therapyandis used with various schedules in Europe, both instage
IIandinstageIIIpatients.High-doseIFN-a2bhasbeenconsidered
the standard of care in North America for patients with an
acceptable performance status. IFN has demonstrated a consistent
impact on RFS, with a modest impact on OS. Observation is still
an appropriate control arm in adjuvant clinical trials. The
population of patients who might beneﬁt from IFN and other
adjuvant treatments needs to be identiﬁed via new technologies of
genomics and proteomics or by identifying novel biomarkers,
which can predict potential host immune responsiveness.
The European melanoma community is currently extremely
activeintheconductofphaseIIItrialsinmelanoma.Ithasplayed
a major role in deﬁning the inefﬁcacy of many adjuvant surgical
procedures in melanoma, and in identifying the incremental
effects of adjuvant IFN in stage II and stage III melanoma
patients.It is hoped thatfuture collaborative studies between the
UnitedStates,AustraliaandEuropewillleadtotheidentiﬁcation
of new and more active treatment modalities for melanoma.
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